The goal of Fibriant’s business strategy is to establish a profitable, sustainable R & D company by developing a suite of recombinant Fibrin(ogen) products with healthcare potential. To achieve this goal Fibriant will follow a step-by-step approach. First the focus will be on the development of the lead product RecoSeel™, a fully recombinant Fibrin sealant used as bio-active topical hemostat to treat surgical bleeding. The R & D pipeline involves the use of specific variants of Fibrinogen for the prevention and treatment of infections caused by the life-threatening MRSA bacteria, recombinant Fibrinogen as injectable hemostat and tailor-made recombinant Fibrin matrices for regenerative medicine applications.
Fibriant’s strategy to generate near-term revenues within the next years is focused on supply of recombinant Fibrinogen and/or recombinant Thrombin, out-licensing IP, technology and know-how, outside the scope of Fibriant’s own product development programs, to other parties.